Biorepository Core B

生物样本库核心B

• 批准号: 10555241
• 负责人: CLAUDIO FIOCCHI
• 金额: $ 22.01万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-02-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10555241
• 关键词: Adipocytes; Area; Basic Science; Biology; Biopsy; Cell Separation; Cells; Chronic; Classification; Clinic; Clinical; Clinical Data; Clinical Investigator; Clinical Laboratory Information Systems; Clinical Research; Colon Carcinoma; Constipation; Consultations; Consumption; Crohn' s disease; DNA; Data Analyses; Diagnosis; Digestive System Disorders; Diverticulosis; Educational process of instructing; Elements; Epidemiology; Epithelial Cells; Esophagus; Experimental Designs; Familial Adenomatous Polyposis Syndrome; Feces; Flow Cytometry; Foundations; Funding; Gastrointestinal tract structure; Genealogy; Generations; Genetic; Genotype; Goals; Human; Human Resources; In Vitro; Individual; Inflammation; Institution; Institutional Review Boards; Intestinal Volvulus; Intestines; Large Intestine; Liver diseases; Logistics; Malignant Neoplasms; Malignant neoplasm of esophagus; Mesentery; Metabolism; Methods; Monitor; Operative Surgical Procedures; Organoids; Patients; Performance; Phenotype; Physicians; Process; Research; Research Activity; Research Institute; Research Personnel; Research Priority; Research Project Grants; Resources; Retrieval; Running; Sampling; Scientist; Serum; Services; Small Intestines; Specimen; System; Time; Tissue Banks; Tissues; Training; Translating; Translational Research; Ulcerative Colitis; Universities; bench to bedside; biobank; cell type; community center; cost effective; cost effectiveness; design; experience; gastrointestinal; genomic platform; improved; member; monolayer; patient oriented research; research study; single cell analysis; success; synergism; translational study; tumorigenesis

BIOREPOSITORY CORE B PROJECT SUMMARY Dr. Claudio Fiocchi is Core Director. Dr. Florian Rieder serves as Associate Director, and Drs. Jean-Paul Achkar, Jennifer Ko and Amitabh Chak serve as Technical Directors. Goals of the Biorepository Core: The specific goals include: 1) Procure, process, and distribute tissue and cells from surgical specimens and biopsies, as well as serum, DNA and stools, from patients with gastrointestinal inflammation, cancer and controls for use in IRB-approved projects of DDRCC members; 2) Provide phenotypic, genotypic, clinical and demographic information of the biosamples; 3) Provide isolation, purification, culture and use of most types of gastrointestinal tract cells; 4) Advise, teach, and supervise investigators on principles, methods, analysis and experimental design; 5) Monitor Core services and continuously evaluate the needs of the DDRCC members to maximally benefit their research priorities, and 6) provide all above services in the most cost-effective and least time-consuming manner. Benefits of the Biorepository Core: During the first 4 years of funding, the objective evidence for the essential benefits of the Cleveland DDRCC Biorepository Core is the fact not a single investigator of the large DDRCC community has failed to receive the type, size or number of biospecimens, as well as the training and logistic support required for his/her studies. This success was achieved by the careful enactment of the specific goals. A new benefit of the Core is a state-of-the-art laboratory information system (LabVantage Solutions-LV), which tracks origin of samples, clinical information, genealogy of samples, and sample retrieval and distribution, and has connectivity to EPIC, Copath, Sunquest, etc. This new system greatly benefits Core users by assuring specimen quality, quick identification, diagnosis and delivery, and formal access to clinical data for interpretation of the experimental results. Finally, the Core has considerably expanded its technical services to include 1) generation of intestinal organoids, 2) organoid-derived epithelial cell monolayers, 3) isolation of mesenteric adipocytes, 4) single cell analysis (Fluidigm C1 and 10X Genomics platforms), 5) CyTOF and spectral flow cytometry systems, and 6) access to a large biobank of esophageal and colon cancer specimens. Overall, the Core benefits DDRCC members by providing unique and high quality biosamples and services.

生物库核心B项目总结 克劳迪奥·菲奥奇博士是核心主任。弗洛里安·里德博士担任副主任，让-保罗博士担任 Achkar、Jennifer Ko和Amitabh Chak担任技术总监。 生物库核心目标：具体目标包括：1)采购、加工和分发组织和 来自手术标本和活检组织的细胞，以及来自胃肠道疾病患者的血清、DNA和粪便。 用于IRB批准的DDRCC成员项目中的炎症、癌症和对照；2)提供表型， 生物样本的基因分型、临床和人口学信息；3)提供分离、纯化、培养和 使用大多数类型的胃肠道细胞；4)就原则向调查人员提供建议、指导和监督， 方法、分析和实验设计；5)监控核心服务并持续评估 DDRCC成员最大限度地受益于他们的研究优先事项，以及6)在 最具成本效益和最少耗时的方式。 生物库核心的好处：在最初4年的资助中，客观证据表明 克利夫兰DDRCC生物信息库核心的主要好处是，没有一个大型研究人员 DDRCC社区未能收到生物杀虫剂的类型、大小或数量，以及培训和 他/她的学习需要后勤支持。这一成功是通过仔细制定具体的 目标。核心的一个新优势是最先进的实验室信息系统(LabVantage Solutions-LV)， 它跟踪样本的来源、临床信息、样本的系谱和样本检索 分发，并连接到EPIC、Copath、SunQuest等。这一新系统极大地惠及核心用户 通过确保样本质量、快速鉴定、诊断和交付以及正式访问临床数据 对实验结果的解释。最后，核心已大大扩展其技术服务，以 包括1)肠类器官的产生，2)类器官衍生的上皮细胞单层，3)分离 肠系膜脂肪细胞，4)单细胞分析(Fluidigm C1和10X基因组学平台)，5)细胞周期分析和 光谱流式细胞仪系统，以及6)获取食道癌和结肠癌样本的大型生物库。 总体而言，核心通过提供独特和高质量的生物样本和服务使DDRCC成员受益。